vs
Side-by-side financial comparison of Invesco Mortgage Capital Inc. (IVR) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $12.6M, roughly 1.7× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 242.2%, a 8.4% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 55.4%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 74.2%).
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
IVR vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $12.6M |
| Net Profit | $51.5M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 242.2% | 250.7% |
| Revenue YoY | 55.4% | 24080.8% |
| Net Profit YoY | 1368.7% | 250.9% |
| EPS (diluted) | $0.72 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | $12.6M | ||
| Q3 25 | $17.6M | $0 | ||
| Q2 25 | $17.7M | $0 | ||
| Q1 25 | $18.8M | $12.0K | ||
| Q4 24 | $13.7M | $52.0K | ||
| Q3 24 | $7.5M | $65.0K | ||
| Q2 24 | $8.6M | $114.0K | ||
| Q1 24 | $7.0M | $140.0K |
| Q4 25 | $51.5M | $31.5M | ||
| Q3 25 | $53.5M | $-7.4M | ||
| Q2 25 | $-23.3M | $-1.7M | ||
| Q1 25 | $19.6M | $-13.9M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $40.7M | $-17.1M | ||
| Q2 24 | $-13.5M | $-17.9M | ||
| Q1 24 | $29.1M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | 242.2% | 250.7% | ||
| Q3 25 | 303.6% | — | ||
| Q2 25 | -131.6% | — | ||
| Q1 25 | 104.4% | -115550.0% | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 542.2% | -26380.0% | ||
| Q2 24 | -155.9% | -15668.4% | ||
| Q1 24 | 415.9% | -9049.3% |
| Q4 25 | $0.72 | $0.56 | ||
| Q3 25 | $0.74 | $-0.13 | ||
| Q2 25 | $-0.40 | $-0.03 | ||
| Q1 25 | $0.26 | $-0.25 | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $0.63 | $-0.32 | ||
| Q2 24 | $-0.38 | $-0.33 | ||
| Q1 24 | $0.49 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $797.5M | $59.0M |
| Total Assets | $6.5B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.0M | $40.3M | ||
| Q3 25 | $58.5M | $48.6M | ||
| Q2 25 | $59.4M | $31.2M | ||
| Q1 25 | $42.9M | $48.9M | ||
| Q4 24 | $73.4M | $52.9M | ||
| Q3 24 | $48.3M | $76.3M | ||
| Q2 24 | $58.8M | $63.5M | ||
| Q1 24 | $59.9M | $82.3M |
| Q4 25 | $797.5M | $59.0M | ||
| Q3 25 | $769.6M | $26.5M | ||
| Q2 25 | $709.4M | $32.8M | ||
| Q1 25 | $759.2M | $33.8M | ||
| Q4 24 | $730.7M | $46.1M | ||
| Q3 24 | $857.0M | $65.5M | ||
| Q2 24 | $759.2M | $80.5M | ||
| Q1 24 | $785.6M | $96.2M |
| Q4 25 | $6.5B | $68.9M | ||
| Q3 25 | $6.0B | $54.2M | ||
| Q2 25 | $5.4B | $62.1M | ||
| Q1 25 | $6.2B | $77.7M | ||
| Q4 24 | $5.7B | $110.5M | ||
| Q3 24 | $6.1B | $135.2M | ||
| Q2 24 | $5.1B | $149.9M | ||
| Q1 24 | $5.2B | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $157.1M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.05× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $157.1M | $-8.4M | ||
| Q3 25 | $37.3M | $17.4M | ||
| Q2 25 | $40.6M | $-17.7M | ||
| Q1 25 | $19.3M | $-4.0M | ||
| Q4 24 | $183.2M | $-23.4M | ||
| Q3 24 | $30.8M | $12.8M | ||
| Q2 24 | $33.0M | $-18.7M | ||
| Q1 24 | $57.5M | $5.9M |
| Q4 25 | 3.05× | -0.26× | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
